Biogen BIIB

NAS: BIIB | ISIN: US09062X1037   2/07/2025
133,19 USD (+2,40%)
(+2,40%)   2/07/2025
Grafiek Biogen Inc. Grafiek Biogen Inc.

Biogen Inc. in het nieuws

30 juni 2025 · Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Primary Membranous Nephropathy · Persbericht

27 juni 2025 · New Data for Nusinersen Underscore Biogen’s Commitment to Advancing Clinical Research to Improve Outcomes in SMA · Persbericht

25 juni 2025 · Biogen to Advance Investigational Spinal Muscular Atrophy Asset to Registrational Studies Based on Positive Interim Phase 1 Results · Persbericht

18 juni 2025 · Biogen Initiates Phase 3 Pediatric Study of Omaveloxolone for the Treatment of Friedreich Ataxia · Persbericht

12 juni 2025 · Dapirolizumab Pegol Phase 3 Data in SLE Presented at the Annual European Congress of Rheumatology (EULAR) Show Improvement in Fatigue and Reduction in Disease Activity · Persbericht

27 mei 2025 · Biogen and City Therapeutics Announce Strategic Research Collaboration to Develop Select Novel RNAi-based Therapies · Persbericht

16 april 2025 · Leqembi®∇ (lecanemab) is the First Medicine that Slows Progression of Early Alzheimer’s Disease to be Authorized in the European Union · Persbericht

2 april 2025 · Biogen’s Investigational Tau-Targeting Therapy BIIB080 Receives FDA Fast Track Designation for the Treatment of Alzheimer’s Disease · Persbericht

24 maart 2025 · Biogen Announces Plans for New Global Headquarters and Innovation Hub in Kendall Square · Persbericht

11 maart 2025 · Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Late Antibody-Mediated Rejection (AMR) in Kidney Transplant Patients · Persbericht

Profiel Biogen Inc.

Biotechnologie
Gezondheidstechnologie
Productie
Productie van biologische producten

Website: www.biogen.com

Hoofdzetel: Cambridge, Massachusetts vlag Verenigde Staten

Mijn selecties